Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells

Stem Cells and Development

Volumn 21, Issue 16, 2012, Pages 2939-2948

  Okabe, Seiichi ^a   Tauchi, Tetsuzo ^a   Tanaka, Yuko ^a   Katagiri, Seiichiro ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; GLIOMA ASSOCIATED ONCOGENE HOMOLOG PROTEIN; ONCOPROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB;

APOPTOSIS; ARTICLE; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; FEEDER CELLS; HEDGEHOG PROTEINS; HUMANS; INTRACELLULAR SPACE; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NUCLEAR PROTEINS; PYRIDINES; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIAZOLES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84867763109     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0016     Document Type: Article

References (21)

1. Sattlermc M and JD Griffin. (2003). Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40:4-10.
2. Kantarjian HM, M Talpaz, F Giles, S O'Brien and J Cortes. (2006). New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145:913-923.
3. Quentmeier H, S Eberth, J Romani, M Zaborski and HG Drexler. (2011). BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 4
4. Wei G, S Rafiyath and D Liu. (2010). First-line treatment for chronic myeloid leukemia dasatinib, nilotinib, or imatinib. J Hematol Oncol 3:47.
5. Sloma I, X Jiang, AC Eaves and CJ Eaves. (2010). Insights into the stem cells of chronic myeloid leukemia. Leukemia 24:1823-1833.
6. Nair RR, J Tolentino and LA Hazlehurst. (2010). The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 80: 602-612.
7. Huntly BJ and DG Gilliland. (2005). Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5:311-321.
8. Ingham PW and M Placzek. (2006). Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet 7:841-850.
9. Scales SJ and FJ de Sauvage. (2009). Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303-312.
10. Peacock CD, Q Wang, GS Gesell, IM Corcoran-Schwartz, E Jones, J Kim, WL Devereux, JT Rhodes, CA Huff, et al. (2007). Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 104:4048-4053.
11. Zhao C, A Chen, CH Jamieson, M Fereshteh, A Abrahamsson, J Blum, HY Kwon, J Kim, JP Chute, et al. (2009). Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458: 776-779.
12. Von Hoff DD, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, GJ Weiss, MJ Borad, CL Hann, et al. (2009). Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172.
13. Ohyashiki K, J Miyauchi, JH Ohyashiki, M Saito, M Yaguchi, Y Inatomi, S Nakazawa, H Wada, S Mizutani, et al. (1992). Interleukin-7 enhances colony growth and induces CD20 antigen of a Ph + acute lymphoblastic leukemia cell line, OM9;22. Leukemia 7:1034-1040.
14. Okabe S, T Tauchi and K Ohyashiki. (2008). Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. Clin Cancer Res 14:6181-6186.
15. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM and PA Beachy. (2002). Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297: 1559-1561.
16. Konopleva MY and CT Jordan. (2011). Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 29:591-599.
17. Colmone A, M Amorim, AL Pontier, S Wang, E Jablonski and DA Sipkins. (2008). Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322:1861-1865.
18. Hegde GV, KJ Peterson, K Emanuel, AK Mittal, AD Joshi, JD Dickinson, GJ Kollessery, RG Bociek, P Bierman, et al. (2008). Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: A potential new therapeutic target. Mol Cancer Res 6:1928-1936.
19. Dierks C, R Beigi, GR Guo, K Zirlik, MR Stegert, P Manley, C Trussell, A Schmitt-Graeff, K Landwerlin, H Veelken and M Warmuth. (2008). Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14:238-249.
20. Sengupta A, D Banerjee, S Chandra, SK Banerji, R Ghosh, R Roy and S Banerjee. (2007). Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21:949-955.
21. Sanchez P and A Ruiz i Altaba. (2005). In vivo inhibition of endogenous brain tumors through systemic interference of Hedgehog signaling in mice. Mech Dev 122:223-230.